Monday, November 6, 2017
- 4:30PM-6:00PM
-
Abstract Number: 1898
Overweight/Obesity Affect Histological Features of Synovial Membrane of Rheumatoid Arthritis Patients from Disease Onset to Stable Remission Achievement
Rheumatoid Arthritis – Clinical Aspects III: Obesity and Other Comorbidities- 4:30PM-6:00PM
-
Abstract Number: 1856
Patient and Physician Perspectives on Content Value for Educational Material Regarding Rare Rheumatic Diseases
ARHP Education/Community Programs- 4:30PM-6:00PM
-
Abstract Number: 1883
Patterns of Osteoarticular Involvement in SAPHO Syndrome: A Cluster Analysis Based on Whole Body Bone Scintigraphy in 157 Patients
Miscellaneous Rheumatic and Inflammatory Diseases I- 4:30PM-6:00PM
-
Abstract Number: 1890
Persistent Fracture Reduction with Abaloparatide-SC (TYMLOS™) Followed By 24 Months of Alendronate
Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis- 4:30PM-6:00PM
-
Abstract Number: 1893
Pharmacokinetics (PK), Pharmacodynamics (PD), and Proposed Dosing of Oral Janus Kinase (JAK)1 and JAK2 Inhibitor Baricitinib in Patients with IFN-Mediated Autoinflammatory Diseases (AIDs)
Pediatric Rheumatology – Clinical and Therapeutic Aspects I: Autoinflammatory Diseases- 4:30PM-6:00PM
-
Abstract Number: 1889
Safety and Efficacy of Denosumab Among Subjects with Mild-to-Moderate Chronic Kidney Disease (CKD) in the “Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months” Extension Study
Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis- 4:30PM-6:00PM
-
Abstract Number: 1907
Safety, Pharmacokinetics, and Efficacy of E6011, an Anti-Fractalkine Monoclonal Antibody, in a First-in-Patient Phase 1/2 Study on Rheumatoid Arthritis: 52-Week Results
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy II: Trials Therapy- 4:30PM-6:00PM
-
Abstract Number: 1895
Serum Interleukin 18 As a Biomarker for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome and Use of Recombinant Human IL-18 BP in a Patient with Refractory Disease
Pediatric Rheumatology – Clinical and Therapeutic Aspects I: Autoinflammatory Diseases- 4:30PM-6:00PM
-
Abstract Number: 1923
Single Cell RNA Sequencing Reveals a Signature of Endothelial Injury in Scleroderma Skin
Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics I- 4:30PM-6:00PM
-
Abstract Number: 1905
Sustained Response Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: Results from a Randomized Controlled Trial
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy II: Trials Therapy- 4:30PM-6:00PM
-
Abstract Number: 1920
Tacrolimus Induces Remission in Refractory and Relapsing Lupus Nephritis By Decreasing P-Glycoprotein Expression and Function on Peripheral Blood Lymphocytes
Systemic Lupus Erythematosus – Clinical Aspects and Treatment III: Biomarkers- 4:30PM-6:00PM
-
Abstract Number: 1887
Ten-Year Continued Nonvertebral Fracture Reduction in Postmenopausal Osteoporosis with Denosumab Treatment
Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis- 4:30PM-6:00PM
-
Abstract Number: 1925
TGFβ Promotes Fibrosis By MYST1-Dependent Epigenetic Regulation of Autophagy
Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics I- 4:30PM-6:00PM
-
Abstract Number: 1872
The Effect of EEG-Amygdala-Related-Neurofeedback on REM Latency in Patients with Fibromyalgia